The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...
Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...
The FDA has doubled down on its decision to remove Eli Lilly’s tirzepatide from its list of products that are in shortage. | ...
The FDA declared the tirzepatide shortage over in October 2023, but a lawsuit by Outsourcing Facilities Association, a trade ...
Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...
The FDA on Thursday confirmed that a shortage of Eli Lilly’s obesity drug tirzepatide has been resolved, a move that will put ...
The Food and Drug Administration (FDA) has reaffirmed that Mounjaro and Zepbound are no longer in shortage following a ...
The U.S. Food and Drug Administration announced Thursday that the shortage of tirzepatide — the active ingredient in Eli ...
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming ...
"Today's approval marks the first drug treatment option for certain patients with obstructive sleep apnea," said Sally ...